Related Experiment Video
Updated: Mar 5, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Jerry F Tien1, Alborz Mazloomian2,3, S-W Grace Cheng1
1Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver V5Z 1L3, Canada.
Abstract:
CDK12 (cyclin-dependent kinase 12) is a regulatory kinase with evolutionarily conserved roles in modulating transcription elongation. Recent tumor genome studies of breast and ovarian cancers highlighted recurrent CDK12 mutations, which have been shown to disrupt DNA repair in cell-based assays. In breast cancers, CDK12 is also frequently co-amplified with the HER2 (ERBB2) oncogene. The mechanisms underlying functions of CDK12 in general and in cancer remain poorly defined. Based on global analysis of mRNA transcripts in normal and breast cancer cell lines with and without CDK12 amplification, we demonstrate that CDK12 primarily regulates alternative last exon (ALE) splicing, a specialized subtype of alternative mRNA splicing, that is both gene- and cell type-specific. These are unusual properties for spliceosome regulatory factors, which typically regulate multiple forms of alternative splicing in a global manner. In breast cancer cells, regulation by CDK12 modulates ALE splicing of the DNA damage response activator ATM and a DNAJB6 isoform that influences cell invasion and tumorigenesis in xenografts. We found that there is a direct correlation between CDK12 levels, DNAJB6 isoform levels and the migration capacity and invasiveness of breast tumor cells. This suggests that CDK12 gene amplification can contribute to the pathogenesis of the cancer.
Insights
Cyclin-dependent kinase 12 (CDK12) primarily regulates alternative last exon splicing, impacting DNA repair and cell invasion in breast cancer. CDK12 amplification correlates with increased tumor cell migration and invasiveness, suggesting a role in cancer development.
Area of Science:
- Molecular Biology
- Cancer Genomics
- Transcriptional Regulation
Background:
- Cyclin-dependent kinase 12 (CDK12) is a regulatory kinase involved in transcription elongation.
- Recurrent CDK12 mutations are found in breast and ovarian cancers, potentially disrupting DNA repair.
- CDK12 is often co-amplified with the HER2 oncogene in breast cancers, but its precise functions remain unclear.
Purpose of the Study:
- To investigate the mechanisms of CDK12 function in cancer.
- To determine the role of CDK12 in breast cancer pathogenesis.
- To analyze the impact of CDK12 amplification on mRNA splicing and tumor cell behavior.
Main Methods:
- Global mRNA transcript analysis in normal and breast cancer cell lines.
- Comparison of cell lines with and without CDK12 amplification.
- Assessment of alternative last exon (ALE) splicing patterns.
- Correlation analysis between CDK12 levels, DNAJB6 isoforms, and cell migration/invasion.
Main Results:
- CDK12 primarily regulates gene- and cell type-specific alternative last exon (ALE) splicing.
- CDK12 modulates ALE splicing of ATM and a DNAJB6 isoform in breast cancer cells.
- CDK12 levels directly correlate with DNAJB6 isoform levels, cell migration, and invasiveness.
Conclusions:
- CDK12's primary role is regulating specific ALE splicing events.
- CDK12 amplification in breast cancer can contribute to pathogenesis by influencing DNA repair and cell invasion.
- Targeting CDK12 may offer therapeutic strategies for breast cancer.
Related Concept Videos
RNA Splicing
Inhibition of Cdk Activity
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Positive Regulator Molecules
Abnormal Proliferation
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

